In 2017,Lili was diagnosed with acute B lymphoblastic leukemia,positive BCR/ABL fusion gene,positive IKZF1 gene mutation,and E255K/V mutation in ABL kinase region at the age of 34 years old.After nearly one year of the combined treatment of targeted drug with chemotherapy in another hospital,the marrow cell morphology was CR and MRD was negative;She underwent haploidentical allogeneic hematopoietic stem cell transplant,but the disease relapsed with T315I mutation just four months after transplant.

Lili came to GHG medial center in 2019,and her condition deteriorated and both lungs were infected at that time.The GHG medial team immediately developed the treatment plan.Treatments including anti-infection,and blood transfusion support were provided together with chemotherapy with targeted drugs to reduce the burden of leukemia.One month later,Lili's general condition was improved,the re-examination of lung CT showed improvement,and symptoms including cough and expectoration disappeared;After the informed consent of her family,murine CD19 CAR-T cells were infused successfully.Only half a month after infusion,the marrow morphology was evaluated as CR,MRD turned negative,and BCR/ABL(p190)quantification result was 0%.Lili and her family were relieved and she was discharged full of happiness.In the follow-up and re-examination afterward,Lili's condition was still in a continuous remission state,and she returned to society and family again upon CAR-T cell therapy.